GPCRs are an ideal vehicle for engineering synthetic signaling systems. These receptors function as signaling switches throughout the body and regulate virtually every physiological response [1] [2] [3] . GPCRs are also the largest gene family targeted for drug discovery 4 . GPCRs stimulate a variety of G-protein pathways; for example, G s stimulates cyclic AMP production, G i inhibits cyclic AMP production, and G q stimulates phospholipase C and releases intracellular calcium stores. Because GPCRs have a relatively simple modular design and are encoded by small genes (usually <1.5 kb), engineered GPCRs can be easily transferred without loss of their functionality into different tissues and species. Therefore, designer GPCRs could be useful for regulating physiologic processes and engineering tissues with stem cells and other technologies.
Attempts to engineer GPCRs that are activated solely by pharmacologically inert drug-like molecules have met with varying degrees of success ( Table 1) . Engineered receptors and engineered receptor-ligand pairs have been created by several approaches and have different names: RASSLs 5 , therapeutic receptoreffector complexes (TRECs) 6 , neoceptors 7 and designer receptors exclusively activated by designer drugs (DREADDs) 8 . Here we refer to them as RASSLs, and we propose a consensus nomenclature ( Table 1) for those in widespread use or in development. This nomenclature links the name of the parent receptor to the major G-protein signaling pathway activated by the receptor.
Engineering RASSLs by directed mutagenesis
In the first attempt to make a designer GPCR, Strader and colleagues developed compounds to selectively activate a mutant version of the β2-adrenergic receptor (β2-AR) that was unresponsive to its natural hormone 9 . They focused on Asp113 3.32 (named using the Ballesteros-Weinstein amino acid numbering system for GPCRs 10 , where 3.32 refers to the third transmembrane segment of the GPCR and residue number 32 of that segment) which is conserved among all biogenic amine GPCRs and is critical for binding terminal amine groups (Fig. 1) . Mutating Asp113 3.32 to serine greatly reduced activation of the β2-AR by biogenic amines. Notably, this mutation allowed the newly synthesized butanone derivative, 1-(3′,4′-dihydroxyphenyl)-3-methyl-1-butanone (L-185,870), to activate the mutant receptor but not the wild-type receptor, albeit with relatively low potency (half-maximum effective concentration, Engineering GPCR signaling pathways with RASSLs the β2-AR 9 ) into the G s -coupled human 5-HT 4 serotonin receptor abolished the ability of serotonin (the endogenous ligand) to activate the receptor but did not affect the activity of many synthetic agonists, including carbazimidamides, benzamides, benzimidazolones and aryl ketones. This RASSL, previously known as Rs1, will be referred to as hRS-s 17 . Many of these synthetic agonists have drug-like properties, nanomolar affinities and readily penetrate the central nervous system, and can therefore be used effectively in vivo 17, 21 . In addition, hRS-s is activated by antagonists of the 5-HT 4 receptor, which have fewer in vivo side effects than 5-HT 4 receptor agonists. Notably, when expressed in osteoblasts of young mice, hRS-s dramatically alters bone growth in vivo 22 , presumably owing to constitutive activation of the G s pathway. These experiments provide valuable insights into the specific cellular and temporal factors that allow G s signaling to induce bone growth.
This same mutagenesis approach of substituting conserved residues of the binding pocket with alanines has been applied to other biogenic amine receptors. Thus, mutation of a conserved serine residue in the fifth transmembrane region (S204 5.46 A) led to a sizeable loss of affinity and efficacy of (-)-adrenaline at α 2A -adrenoceptors (G i/o -coupled receptors), and the mutated receptor could still be activated by synthetic agonists (UK14304 and clonidine) or even by antagonists of the wild-type receptor (atipamezole and SKF86466) 23 . Similarly, a G q/11 -coupled RASSL was developed by introducing the F435 6 .55 A mutation into the histamine H 1 receptor 18 . This RASSL could be activated by high concentrations of endogenous histamine and had improved affinity and potency for 2-phenylhistamines, a EC 50 , = 118 µM) 9 . Although this original report was inspiring, the synthetic agonist had low affinity and unknown pharmacokinetics that rendered it impractical for in vivo use.
The first engineered receptor or RASSL activated by an agonist with nanomolar affinity suitable for in vivo use was reported by Coward and colleagues 5 , who took advantage of potent synthetic drugs originally developed as potential analgesics, such as κ-opioid receptor agonists (for example, spiradoline). The first RASSL was created by introducing mutations in the κ-opioid receptor that abrogated signaling via the natural peptide ligands yet preserved stimulation by spiradoline 5 . This engineered human RASSL, human RASSL opioid G i -coupled receptor (hRO-i), referred to as Ro1 (ref. 5) , has been expressed in at least six tissues in transgenic mice (Fig. 2) . This expression resulted in the induction of various phenotypes including ligand-dependent heart-rate modulation 11 , and bitter and sweet taste sensations 12, 13 as well as ligand-independent cardiomyopathy 14 , hydrocephalus 15 and osteopenia 16 . These exciting results fueled efforts to develop RASSLs with improved ligand pharmacology and a greater range of signaling responses.
Once scientists understood that RASSLs could be designed to work with existing drugs, new RASSLs soon emerged from studies of a wide variety of receptors, including the 5-HT 4 serotonin 17 , β2-adrenergic 6 , H 1 -histamine 18 , A3 adenosine 7 , 5-HT 2A -serotonin 19 and MC4-melanocortin 20 receptors. In most of these receptors, scientists targeted key residues essential for binding the native ligand by site-directed mutagenesis. For example, introduction of the D100 3.32 A mutation (analogous to the D113 3.32 A mutation in compounds without known molecular targets). This technique is likely to be widely used to create designer GPCRs, owing to the availability of strains of yeast (Saccharomyces cerevisiae) engineered to express and respond to human GPCRs 25, 26 . When these GPCRexpressing yeast are activated by an agonist, the signal induces the expression of a variety of selectable markers under control of a Fus-1 promoter. This system allows for the facile screening and optimization of millions of mutant GPCRs in a relatively short time 27 . Dozens of human GPCRs have been expressed in yeast 28 , thereby opening up the potential to create families of designer GPCRs activated by specific small molecules.
RASSLs as molecular switches for tissue engineering
RASSLs may be valuable in controlling growth and ensuring appropriate control of function for experimental or therapeutic tissue engineering. GPCR signaling is essential for the growth and differentiation of many tissues 2 . For example, the 5-HT 2B serotonin receptor is required for cardiac development and cell-cycle progression [29] [30] [31] . Ectopic signaling via GPCRs can promote abnormal growth 3 , leading to human disease. For instance, drug-induced valvular heart disease may be caused by excessive stimulation of cardiac 5-HT 2B receptors 32 . One can envision the use of RASSLs to activate discrete signaling pathways to promote the proper growth and differentiation of engineered tissues. Another potential use of RASSLs is to gain precise control of signaling in neurons and other tissues. Currently, this control in defined neuronal populations can be facilitated by expressing RASSLs in a neuron-specific manner. We reported that CNO-mediated activation of the G i -coupled hRMD-i induces neuclass of synthetic H 1 R agonists (2-[3-chlorophenyl]histamine) . Notably, alternative substitutions at this position (Phe435 6.55 ) resulted in RASSLs with different levels of constitutive activity; F435 6.55 A (hRH-s) had the lowest level of constitutive signaling.
Creating RASSLs by directed molecular evolution Despite these noteworthy advances, first-generation RASSLs were not ideal for experimentation. The ligands of first-generation RASSLs activated endogenous receptors (for example, κ-opioid, H1-histamine, 5-HT 4 -serotonin and MC4-melanocortin receptors), or had low affinities for the mutated receptor (A3-adenosine neoceptor, β2-AR TREC and 5-HT 2A serotonin RASSL). Moreover, profound phenotypes induced by constitutive activity were observed upon RASSL overexpression in vivo (RO-i and RS-s). Lastly, development of new RASSLs by repeated cycles of directed mutagenesis was labor-intensive and did not consistently yield receptors with ideal agonist affinities or controlled constitutive signaling. To overcome these inherent difficulties, we developed a generic approach to create a new class of RASSLs that have low constitutive activity and respond specifically to drug-like, pharmacologically inert small molecules 8 .
We used a well-established yeast mutagenesis system to produce hundreds of thousands of mutant hM 3 muscarinic receptors and screened them for signaling characteristics of an 'ideal' RASSL 8 . After multiple rounds of mutagenesis and iterative screening, we isolated mutants that had lost the ability to respond to the natural ligand (acetylcholine) but gained the ability to respond with nanomolar potency to clozapine-N-oxide (CNO), a pharmacologically inert, bioavailable 24 synthetic compound (Fig. 3) . We designated this new class of RASSLs as DREADDs (ref. 6). We refer to this first DREADD as hRMD-q (RASSL M 3 muscarinic receptor DREADD, G q -coupled; referred to as hM3-D in ref. 6 ). The hRMD-q receptor is insensitive to acetylcholine but activates the G q pathway to induce calcium mobilization upon binding of CNO. Analogous mutations in the closely related M 4 muscarinic receptor, which is G i -coupled and inhibits cyclic AMP accumulation, led to another RASSL or DREADD that we call hRMD-i (referred to as hM 4 D in ref. 8) . When activated by CNO, hRMD-i silenced hippocampal neurons via Gβγ-mediated activation of G-protein inwardly rectifying K + (GIRK) channels 8 . It is likely that hRMD-i will be widely used to induce neuronal silencing in vivo via indirect activation of GIRKs. More recently, researchers made chimeras of the rat equivalent of the hRMD-q that incorporates the second and third intracellular loops of the G s -coupled β1-adrenergic receptor to create a G s -coupled RASSL (rRMD-s; With the current DREADD-type RASSLs, only two point mutations were required to create hRMD-i and hRMD-q. By contrast, creation of rRMD-s required two point mutations and swapping of two intracellular loops. Creating other DREADD-type RASSLs by directed molecular evolution will likely require at least multiple point mutations based on our experience (Y.P. et al., manuscript in preparation). Thus far, all of the point mutations have been found in or near predicted binding sites for orthosteric ligands.
The general method we devised evolves GPCR ligand specificity toward pharmacologically 'inert' ligands (for example, drug-like PERSPECTivE expression in diverse tissues with tighter temporal control. The second-generation RASSLs (hRMD-q, hRMD-i, rRMD-s) were created to lack constitutive activity 8 , and thus far, their overexpression in mice has not elicited baseline phenotypes (S. Rogan, B.L.R., J.-M.G. and J.W., unpublished observations). These second-generation RASSLs will be most useful for studies in which ligand-dependent effects rather than baseline phenotypes are sought.
Future directions
The RASSL field has undergone dramatic growth in the past decade, but many more challenges lie ahead. For instance, the ideal family of RASSLs would respond to a clinically approved, physiologically inert drug (for example, antibiotic or antiviral) that has no intrinsic effect on human cells, allowing tissue engineering without the drug safety studies needed for relatively new compounds such as CNO. The optimal RASSLs would also selectively couple to each of the GPCR pathways, including noncanonical pathways, such as those involving arrestins, GRKs and other intracellular kinases 30 . Furthermore, each RASSL would have different constitutive responses, desensitization properties, and subcellular targeting that could be fine-tuned by introducing simple mutations. For many of these goals, we will need spatiotemporal control of RASSL expression to allow for direct comparisons of RASSL actions that could be applicable to virtually any tissue. Several groups are now testing a variety of approaches (bacterial artificial chromoronal silencing when expressed in hippocampal neurons 8 . When expressed in hippocampal neurons, hRMD-q induces neuronal excitation and intracellular Ca 2+ release in CNO-dependent fashion (S. Rogan and B.L.R., manuscript in preparation). Using these two engineered muscarinic receptors, one could gain precise bidirectional control of neuronal firing in vitro and in vivo. These modified receptors could also be used in other excitable tissues, such as cardiac pacemaker cells, where G s stimulation speeds diastolic depolarization and accelerates heart rate, and G i stimulation slows heart rate. Expression of different G s (for example, hRS-s or rRMD-s) and G i (for example, RO-i or hRMD-i) RASSLs in pacemaker cells could allow for the precise regulation of heart rate without affecting cardiac muscle function.
The importance of constitutive signaling by RASSLs
In studies of first-generation RASSLs expressed in vivo, constitutive signaling (constitutive activity) has often produced the most profound effects. Overexpression of a G i -coupled RASSL (hRO-i) in cardiomyocytes led to cardiomyopathy 14 , whereas overexpression in osteoblasts led to osteoporosis 16 . Recently a G s RASSL (hRS-s) expressed in osteoblasts induced marked bone growth 16 . Constitutive activity is a common property of native GPCRs 33, 34 and is essential for the normal function of certain GPCRs 35 . Therefore, RASSLs with different levels of constitutive activity (high and low) will be needed to recapitulate normal GPCR functions. Because of the potential ligand-independent effects, RASSL expression ideally should be controlled through conditional expression systems (for example, tetracycline-inducible or Cre-loxP). With these systems, a single RASSL transgenic line can be used to drive Shown is a generic scheme for obtaining RASSLs via directed molecular evolution. In brief, a large library of randomly mutated GPCRs is obtained by error-prone PCR and used to efficiently transform the appropriate yeast strain. Yeast with functional GPCRs is grown in uracil-and histidine-deficient medium in the presence of the inert ligand (in this case, CNO), and surviving colonies are expanded and characterized pharmacologically. GPCRs with the appropriate pharmacological profiles are subjected to iterative rounds of additional mutagenesis and selection until the ideal RASSL is obtained. Candidate RASSLs are subjected to growth assays in the presence and absence of candidate ligands to screen out those with elevated constitutive activity. Typically several candidate inert ligands are used in the initial screens to determine which are most suitable for directed molecular evolution, and then one or more are chosen for testing. The final choice of the candidate ligand is based on its potency and drug-like properties.
some transgenics, knock-ins and inducible systems) to meet these new challenges and provide new tools to RASSL researchers. With these highly refined tools, biologists will have a better understanding of how to use RASSLs and GPCR signaling pathways for tissue engineering.
The cross-disciplinary nature of RASSL-related research fosters a highly collaborative community that makes protocols, reagents and transgenic animals publicly available whenever possible. Even though individual members of the RASSL community initially created tools specifically for their own research, the potential uses of these tools go well beyond any individual project. Indeed, precisely because GPCR signaling is important to such a wide swath of biology, it is impossible for us to accurately predict how and where RASSLs will be ultimately used.
We anticipate that our RASSL delivery systems will be deployed for a wide range of tissue engineering applications in neurological disease, pain perception, immunology, bone metabolism and diabetes. In each case, our efforts will provide enabling technologies to rapidly advance those fields. For instance, in many neurological diseases (for example, Parkinson's disease), RASSLs may be useful for correcting the imbalance of neural pathways, in a manner that could complement the surgical or electrical approaches in current clinical practice. Similarly, many groups envision using tissue-engineering approaches to study pain perception pathways. RASSLs, which selectively modulate neuronal firing, could be ideal for this application. Although GPCRs are clearly important in bone metabolism, many key receptors signal via multiple pathways and exhibit constitutive signaling. RASSLs will also allow researchers to stimulate discrete signaling pathways in bone metabolism. Finally, in diabetes, GPCRs have a role in the growth, development and function of insulin-secreting pancreatic β-cells 36 . Dissecting the precise roles of different G-protein signaling pathways in β-cell function should be of considerable therapeutic interest.
Perhaps most importantly, the use of RASSL technology may shed light on relatively unknown aspects of GPCR signaling. For instance, many researchers are investigating nonclassical signaling responses of GPCRs, such as signaling by G 12/13 , arrestins, receptor kinases, regulators of G protein signaling, Wnt receptor signals and scaffolding proteins 30 . It should be of interest to create two RASSLs that only differ in their ability to activate the arrestin pathways. Expression of these two RASSLs in the same spatial and temporal pattern would then allow determination of the true physiological roles of arrestin signaling.
Some of these non-G-protein signaling pathways could prove essential for robust tissue engineering and for uncovering the pathways responsible for stem cell differentiation. One can envision scenarios in which RASSLs are selectively expressed in different stem cell lineages and then activated (with an exogenous ligand or by overexpression) to determine which pathways are responsible for lineage choices and tissue differentiation.
